Biophytis jumps on expanded access for COVID-19 treatment in Brazil

Biophytis SA

03/02/2022 11:47

** U.S.-listed shares of France-based biotech co  BPTS.O 
jump 19.5% to $5.56 premarket, set for their best day 
    ** Stock among top performers across exchanges
    ** Co receives approval from Brazil's health regulatory
agency to give access to its drug candidate, sarconeos, to
hospitalized COVID-19 patients through an expanded access
program (https://bit.ly/3ro5ecY)
    ** Sarconeos treatment will be given to a maximum of 80
patients mechanically ventilated in ICUs of Brazilian hospitals
    ** Sarconeos is also being developed to treat neuromuscular
diseases
    ** Stock down ~13% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))